Levelling the playing field

Two-thirds of new drugs now come from emerging biopharma companies. The ones inventing tomorrow's medicines are the ones almost nobody writes about.* Yet innovative science only progresses if someone funds it — and investors fund what they understand.

The information is out there — but it's a haystack: filings, press releases, forums, automated headlines. Investors used to rely on bank analysts to find the needle. Increasingly, they also ask AI — an extra layer that broadens their view in seconds, about any company, built from whatever it can read.

5mn doesn’t add to the haystack, it sharpens the needle: five minutes, one company, and the one question that moves the stock, published in the open and structured so that AI can find it.

Better-informed investors fund better science. Better-funded science reaches patients.